M Anwar Iqbal

Dr. M Anwar Iqbal


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2025 in American Journal of Hematology
Verified
Journal Article
Open access
Rashmi Kanagal-ShamannaRashmi Kanagal-Shamanna
Rashmi Kanagal-Shamanna
APAnna Puiggros
Anna Puiggros
IGIsabel Granada
Isabel Granada
GRGordana Raca
Gordana Raca
KRKatrina Rack
Katrina Rack
BEBlanca Espinet
Blanca Espinet
The latest updates to the classification of hematolymphoid malignancies using the World Health Organization (WHO, 5th ed.) and ICC (International Consensus Classification) criteria highlight the critical need for comprehensive and precise cytogenomic data for diagnosis, prognostication, and treatment. This presents significant challenges for clinical laboratories, requiring a complex workflow using multiple assays to detect different types of structural chromosomal variants (copy number changes, fusions, inversions) across the entire genome. Optical genome mapping (OGM) is an advanced cytogenomic tool for genome‐wide detection of structural chromosomal alterations at the gene/exon level. Studies demonstrate that OGM facilitates the identification of novel cytogenomic biomarkers, improves risk stratification, and expands therapeutic targets and personalized treatment strategies. OGM is easy to implement and highly accurate in detecting structural variants (SVs) across various diagnostic entities. Consequently, many centers are integrating OGM into the clinical cytogenetic workflow for hematological malignancies. However, systemic clinical adoption has remained limited due to the lack of expert recommendations on clinical indications, testing algorithms, and result interpretation. To address this, experts from the International Consortium for OGM and relevant multidisciplinary fields developed recommendations for the integration of OGM as a standard‐of‐care cytogenetic assay for the diagnostic workflow in various clinical settings. These recommendations standardize the use of OGM across laboratories, ensure high‐quality cytogenetic data, guide clinical trial design and development, and provide a basis for updates to diagnostic and classification models.

1 July 2012 in Leukemia Research
Verified
Journal Article
Closed access
ACAthena M. Cherry
Athena M. Cherry
MSMarilyn L. Slovak
Marilyn L. Slovak
LCLynda J. Campbell
Lynda J. Campbell
KCKathy Chun
Kathy Chun
VEVirginie Eclache
Virginie Eclache
GDGordon W. Dewald
Gordon W. Dewald

27 February 2023 in Genes
Verified
Journal Article
Open access
PDF file
AAAusaf Ahmad
Ausaf Ahmad
DNDingani Nkosi
Dingani Nkosi
MIM Anwar Iqbal
M Anwar Iqbal
The PARK2 gene is located on 6q26, encodes ubiquitin-E3- ligase, and is a transcriptional repressor of p53. It contains 12 exons. PARK2 copy number variants has been reported in various types of neurodevelopmental disorders, namely schizophrenia, Parkinson’s disease (PD), autism spectrum disorder (ASD), and attention-deficit/hyperactivity disorder (ADHD). In this retrospective study, nine cases (five with microdeletion and four with microduplication) are reported with 6q26 deletion disrupting the PARK2 gene. Microdeletion sizes ranged between 215 Kb and 356 Kb, and duplication between 279 Kb and 726 Kb. These were present within the exons 7–10. Family follow up with FISH probes revealed paternal inheritance in two cases, maternal in two cases, and de novo origin in one case. Our results support previous studies showing that patients with PARK2 CNVs involving exons 5–12 might be more deleterious and cause a unique syndrome. Comprehensive analysis of additional case studies is needed to have a full characterization of this neurological disorder syndrome.

1 December 2010 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
NKNamik Kaya
Namik Kaya
SASaleh Al-Muhsen
Saleh Al-Muhsen
BABandar Al-Saud
Bandar Al-Saud
MIM Anwar Iqbal
M Anwar Iqbal
DCDilek Colak
Dilek Colak
MIMohammad Iqbal
Mohammad Iqbal

20 November 2012 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MVMilen Velinov
Milen Velinov
AAAusaf Ahmad
Ausaf Ahmad
BBBrigette Brown‐Kipphut
Brigette Brown‐Kipphut
MSMustafa Shafiq
Mustafa Shafiq
JBJonathan Blau
Jonathan Blau
MIM Anwar Iqbal
M Anwar Iqbal

9 December 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
APAndy W. C. Pang
Andy W. C. Pang
KKKarena Kosco
Karena Kosco
NSNikhil Shri Sahajpal
Nikhil Shri Sahajpal
ASArthi Sridhar
Arthi Sridhar
JHJen Hauenstein
Jen Hauenstein
ACAlka Chaubey
Alka Chaubey
Structural variations (SVs) play a key role in the pathogenicity of hematological malignancies. Standard-of-care (SOC) methods such as karyotyping and fluorescence in situ hybridization (FISH), which have been employed globally for the past three decades, have significant limitations in terms of resolution and the number of recurrent aberrations that can be simultaneously assessed, respectively. Next-generation sequencing (NGS)-based technologies are now widely used to detect clinically significant sequence variants but are limited in their ability to accurately detect SVs. Optical genome mapping (OGM) is an emerging technology enabling the genome-wide detection of all classes of SVs at a significantly higher resolution than karyotyping and FISH. OGM requires neither cultured cells nor amplification of DNA, addressing the limitations of culture and amplification biases. This study reports the clinical validation of OGM as a laboratory-developed test (LDT) according to stringent regulatory (CAP/CLIA) guidelines for genome-wide SV detection in different hematological malignancies. In total, 60 cases with hematological malignancies (of various subtypes), 18 controls, and 2 cancer cell lines were used for this study. Ultra-high-molecular-weight DNA was extracted from the samples, fluorescently labeled, and run on the Bionano Saphyr system. A total of 215 datasets, Inc.luding replicates, were generated, and analyzed successfully. Sample data were then analyzed using either disease-specific or pan-cancer-specific BED files to prioritize calls that are known to be diagnostically or prognostically relevant. Sensitivity, specificity, and reproducibility were 100%, 100%, and 96%, respectively. Following the validation, 14 cases and 10 controls were run and analyzed using OGM at three outside laboratories showing reproducibility of 96.4%. OGM found more clinically relevant SVs compared to SOC testing due to its ability to detect all classes of SVs at higher resolution. The results of this validation study demonstrate the superiority of OGM over traditional SOC methods for the detection of SVs for the accurate diagnosis of various hematological malignancies.